RESUMEN
This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focused on prediction, diagnosis, and management of fibrostenosing Crohn's disease [CD]. The objective was to achieve evidence-supported, expert consensus that provides guidance for clinical practice.
Asunto(s)
Enfermedad de Crohn/fisiopatología , Obstrucción Intestinal/diagnóstico , Obstrucción Intestinal/terapia , Antiinflamatorios/uso terapéutico , Biomarcadores/metabolismo , Enfermedad de Crohn/genética , Enfermedad de Crohn/patología , Dilatación , Endoscopía Gastrointestinal , Fibrosis/diagnóstico , Fibrosis/terapia , Predisposición Genética a la Enfermedad , Humanos , Mucosa Intestinal/metabolismo , Obstrucción Intestinal/etiología , Obstrucción Intestinal/patología , Intestinos/patología , Intestinos/cirugía , Laparoscopía , Pronóstico , Factores de RiesgoRESUMEN
Gastroesophageal reflux disease is increasingly associated with ear, nose, and throat symptoms, including laryngitis. Many patients are unaware of the gastroesophageal etiology of their symptoms. A variety of criteria are used to diagnose this condition, including laryngoscopy, esophagogastroduodenoscopy, and the use of ambulatory pH and impedance monitoring. However, no test serves as the gold standard for the diagnosis given their lack of sensitivity and specificity for reflux disease. Numerous trials have assessed the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux and most have revealed no benefit to acid suppression over placebo. Despite many uncertainties there has been some progress regarding the role of acid-suppressive therapy as well as other agents in this unique group of patients. In this review we explore therapeutic options and their rationale for patients with laryngeal signs and symptoms.
